FDA Approves Zappy Device to Zap Away Nose Congestion Woes
Published Date: 4/16/2026
Rule
Summary
The FDA is officially putting the transcutaneous electrical nerve stimulator for congestion relief into a safer, easier-to-get category called Class II. This change means the device will have special safety rules but fewer red tape hurdles, helping patients get access to this cool tech faster. The new classification is effective April 16, 2026, and could save companies time and money while keeping users safe.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Patients: Faster Access to Device
The FDA officially placed the transcutaneous electrical nerve stimulator for relief of congestion into Class II, effective April 16, 2026 (classification was applicable March 5, 2021). The agency says this Class II classification reduces regulatory burdens and will enhance patients' access to the device.
Makers Face Lower Regulatory Hurdle
The De Novo classification puts this device in Class II rather than leaving it automatically in Class III, which reduces regulatory burdens and can save companies time and money compared to premarket approval. FDA states the action will enhance access to innovation in part by reducing regulatory burdens.
New Testing and Labeling Requirements
To be marketed as Class II, the device must meet special controls including non-clinical performance testing; electromagnetic compatibility, battery safety, and electrical safety testing; software verification, validation, and hazard analysis; biocompatibility of patient-contacting components; human factors testing; and labeling with instructions and detailed device specifications (e.g., number of channels, output waveform, stimulation peak voltage and current, pulse duration, frequency, maximum current density, maximum phase charge, and power source).
Creates Predicate for Future Devices
FDA states that when a device is classified into Class II via the De Novo process, that device can serve as a predicate for future, substantially equivalent devices, allowing other sponsors to use the less burdensome 510(k) premarket notification process instead of De Novo or premarket approval.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in